ArticleArthritis research & therapy2026
Immunoglobulin G and plasma glycome in early rheumatoid arthritis differ from matched controls and link less fat-free mass to an accelerated aging phenotype: an exploratory study.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
Weight Loss and Exercise To Improve Rheumatoid Arthritis Cardiovascular Risk
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundIn patients with rheumatoid arthritis (RA), the immunoglobulin G (IgG) glycome is altered and characterized by decreased galactosylation. The goals of our exploratory study were to identify (1) alterations in the IgG and plasma glycome and GlycanAge—a glycome-based biological age measure—in patients with early RA and (2) changes in the RA glycome following a lifestyle intervention.
methodsIgG and plasma glycome and clinical and physiological parameters were analyzed from two cohorts: (1) participants with early RA (symptom duration < 6 months; n = 10) and age-, sex- and BMI-matched healthy controls (n = 10); and (2) older participants (age > 60) with RA (n = 20) who completed a diet and exercise intervention.
resultsAs compared to controls (chronologic age = 53.2 ± 12.3 years), early RA (chronologic age = 53.6 ± 12.9 years) had a GlycanAge corresponding to 18.1 years older (42.1 ± 25.3 versus 60.2 ± 19.5 years; p = 0.03), greater plasma tetra-galactosylated, tri-sialylated, tetra-sialylated, and antennary fucosylated glycans, and lesser plasma mono-sialylated and oligomannan glycans (p < 0.05 for all). Controlling for chronologic age and sex, RA (n = 39) GlycanAge was negatively associated with cardiorespiratory fitness (V̇O2 peak, mL/kg/min; beta=-1.66, p = 0.005) and fat-free mass (kg; beta=-1.77, p = 0.004). While a diet and exercise lifestyle intervention for RA (n = 20) did not significantly alter glycome parameters, reductions in GlycanAge were associated with increases in fat-free mass (Spearman rho=-0.46, p = 0.04).
conclusionChanges in the RA glycome occur early in the RA disease process and may be useful as biomarkers for RA diagnosis and monitoring. Further study is needed to explore the potential for lifestyle interventions targeting improvements in cardiorespiratory fitness and body composition to impact the glycome and accelerated biological aging linked to RA.
trial registrationClinicalTrials.gov, NCT04226131, registered on January 13, 2020 NCT04356183, registered on April 22, 2020.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.